Can Diffusion Tensor Imaging (DTI) of the Optic Ways Contributes to Predict the 6 Months Prognosis of Optic Neuritis (ON)?

NCT ID: NCT03570385

Last Updated: 2022-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-04

Study Completion Date

2022-06-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Can diffusion tensor imaging (DTI) of the optic ways contributes to predict the 6 months prognosis of Optic Neuritis (ON)?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Optic Neuritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Interventional pilot study with minimal risks and constraints, descriptive, prospective, monocentric
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with Optic Neuritis

Group Type EXPERIMENTAL

MRI

Intervention Type DEVICE

MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 to 55 years old
* Clinically suspected optic neuritis defined as a sudden decrease of the visual acuity and/or a damage to the field of vision and/or a defect of the colour vision and/or retro-orbital pain with a relative afferent pupillary defect (except if the optic neuropathy is bilateral or symmetrical), in the absence of a severe retinal macular pathology, and in the absence of a toxic or iatrogenic intake (ethambutol, vfend)
* Clinical optic neuritis duration \< 15 days
* First episode of an inflammatory ON
* No corticosteroids in the month before
* Indication to a corticosteroid therapy at high dose to cure the felt symptomatology
* Retinal nerve fibre layer (RNFL) thickness upper 75 µm at initial stage
* Isolated ON, multiple sclerosis or NMO (Neuro Myelitis Optica) - SD (Spectrum Disorder) context
* Having signed informed consent for participating in the study

Exclusion Criteria

* Contra-indication to MRI

* Cardiac pacemaker or defibrillator implant
* Neurosurgical clips
* Cochlear implants
* Intra-orbital or encephalic foreign bodies
* Stents implanted since less than 4 weeks and osteosynthesis equipment implanted since less than 6 weeks
* Claustrophobia
* Persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty
* Eye examination suggests a pre-existing eye abnormality that could affect the visual function (amblyopia, strong myopia…)
* Pregnant or breastfeeding women
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rennes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Rennes

Rennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

35RC17_8828_DTI et NOI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Imaging in Demyelinating Diseases
NCT05805839 ENROLLING_BY_INVITATION PHASE2